Abstract
Therapeutic management of cancer has undergone tremendous conceptual advance over the last couple of decades. Not only are we better acquainted with the intricate mechanisms leading to oncogenic transformation, but also the strategies to intercept and disturb these command and control pathways are becoming more specific and target-selective. One critical change is the realization that despite the existence of diverse mechanisms for the development of different sub-sets of cancers, there may indeed be central regulatory networks that serve as a common denominator in all forms of neoplasia. These critical events could endow cells with the potential for unabated proliferation, insensitivity to death inducing signals, and enhanced metastatic potential. Thus, developing strategies to target these critical events or pathways should significantly improve the outcome of cancer chemotherapy. The purpose of this review is to briefly discuss the complexities of the disease, highlight the current therapeutic strategies, and more importantly provide a mechanistic approach for future drug design aimed at targeting the traits of the disease and for favorably tailoring the response of cancer cells to drug therapy.
Keywords: anti-cancer drugs, curing cancer, therapeutic management, neoplasia, drug therapy, mechanistic approach to the design, antibiotics, novel strategies, fptase activity, remortalize the immortal
Current Pharmaceutical Design
Title: Anti-Cancer Drugs of Today and Tomorrow: Are we Close to Making the Turn from Treating to Curing Cancer?
Volume: 8 Issue: 19
Author(s): Shazib Pervaiz
Affiliation:
Keywords: anti-cancer drugs, curing cancer, therapeutic management, neoplasia, drug therapy, mechanistic approach to the design, antibiotics, novel strategies, fptase activity, remortalize the immortal
Abstract: Therapeutic management of cancer has undergone tremendous conceptual advance over the last couple of decades. Not only are we better acquainted with the intricate mechanisms leading to oncogenic transformation, but also the strategies to intercept and disturb these command and control pathways are becoming more specific and target-selective. One critical change is the realization that despite the existence of diverse mechanisms for the development of different sub-sets of cancers, there may indeed be central regulatory networks that serve as a common denominator in all forms of neoplasia. These critical events could endow cells with the potential for unabated proliferation, insensitivity to death inducing signals, and enhanced metastatic potential. Thus, developing strategies to target these critical events or pathways should significantly improve the outcome of cancer chemotherapy. The purpose of this review is to briefly discuss the complexities of the disease, highlight the current therapeutic strategies, and more importantly provide a mechanistic approach for future drug design aimed at targeting the traits of the disease and for favorably tailoring the response of cancer cells to drug therapy.
Export Options
About this article
Cite this article as:
Pervaiz Shazib, Anti-Cancer Drugs of Today and Tomorrow: Are we Close to Making the Turn from Treating to Curing Cancer?, Current Pharmaceutical Design 2002; 8 (19) . https://dx.doi.org/10.2174/1381612023394025
DOI https://dx.doi.org/10.2174/1381612023394025 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genetically Modified Endothelial Progenitor Cells in the Therapy of Cardiovascular Disease and Pulmonary Hypertension
Current Vascular Pharmacology Atherosclerotic and Non-Atherosclerotic Coronary Heart Disease in Women
Current Medicinal Chemistry Pharmacologically Targeting the Primary Defect and Downstream Pathology in Duchenne Muscular Dystrophy
Current Gene Therapy Proteomic and Bioinformatic Analysis of Trypanosoma cruzi Chemotherapy and Potential Drug Targets: New Pieces for an Old Puzzle
Current Drug Targets Platelet and Soluble Glycoprotein VI - Novel Applications in Diagnosis and Therapy
Current Drug Targets MicroRNA-34a Promotes Cardiomyocyte Apoptosis Post Myocardial Infarction Through Down-regulating Aldehyde Dehydrogenase 2
Current Pharmaceutical Design Safety Analysis and Improved Cardiac Function Following Local Autologous Transplantation of CD133+ Enriched Bone Marrow Cells After Myocardial Infarction
Current Neurovascular Research Physical Activity and Diabetic Cardiomyopathy: Myocardial Adaptation Depending on Exercise Load
Current Diabetes Reviews Ectodomain Shedding of ACE and ACE2 as Regulators of Their Protein Functions
Current Enzyme Inhibition Inhibition of Histone Deacetylases: A Pharmacological Approach to the Treatment of Non-Cancer Disorders
Current Topics in Medicinal Chemistry Postoperative Care of the Transplanted Patient
Current Cardiology Reviews Cannabinoid Receptor Type 2 Activation in Atherosclerosis and Acute Cardiovascular Diseases
Current Medicinal Chemistry Therapeutic Targets for the Management of Peripheral Nerve Injury- Induced Neuropathic Pain
CNS & Neurological Disorders - Drug Targets Clinical and Pharmacological Aspects of Immunoprophylaxis for Respiratory Syncytial Virus Infection in High-Risk Infants
Current Drug Metabolism Editorial (Thematic Issue: Managing Strategies for Diverse Diseases: Challenges from Bench to Bedside Translation in Successful Drug Discovery and Dev elopment (Part C))
Current Pharmaceutical Design Matrix Metalloproteinases as Valid Clinical Target
Current Pharmaceutical Design Insights Into the Role of microRNAs in Cardiac Diseases: From Biological Signalling to Therapeutic Targets
Cardiovascular & Hematological Agents in Medicinal Chemistry Prognostic Implications of Genetics in Cardiovascular Disease
Current Pharmacogenomics Endothelial Dysfunction in Heart Failure: Mechanisms and Therapeutic Approaches
Current Vascular Pharmacology Phenotypic Screening for Pharmaceuticals Using Tissue Constructs
Current Pharmaceutical Biotechnology